Dialog Box

What is CF?

Cystic fibrosis is a genetic condition

Cystic fibrosis (also called CF) is the most common, life-limiting genetic condition affecting Australians. 

CF causes an abnormal build-up of thick and sticky mucus in the lungs, airways and digestive system. Treatment requires intensive daily physiotherapy to clear the lungs and airways, countless medications and frequent hospitalisations.

Find out more Get support

Living with CF

Everyone's experience with CF is different


Learn more about CF so you can be confident in managing your child's condition.

Read more
Young People

During your teenage years, you start to take over more management of CF from your family.

Read more

Tools, information and advice to support you to live your life while managing CF.

Read more

When you care for someone living with CF, looking after yourself needs to be important part of the plan.

Read more

Fundraise for us

It takes a community to care for CF

Every donation received and every dollar raised no matter how big or small, has the power to make a difference to the life of someone living with cystic fibrosis. All funds raised for Cystic Fibrosis Community Care help us to deliver support services and improve the lives of people living with CF, their families and carers.

Fundraise Donate

Our impact

We provide practical support


 subsidised items of physiotherapy equipment


responses to requests for information, support & advocacy


responses to requests for emergency financial assistance


responses to requests for education support

Who are the people living with Cystic Fibrosis?

3,500 people are living with CF in Australia and 1 in 25 people carry the recessive CF gene change. Babies born today with CF can expect to live well into adulthood. There is no cure but advances in treatment and care are helping people to better manage their condition.

Latest News View all news


As advancements in medical research continue to unfold, hope brightens for individuals living with cystic fibrosis (CF).


Approximately 300 families with children aged 2-5 who have at least one F508del mutation, are waiting for Trikafta. With the Pharmaceutical Benefits Advisory Committee meeting being held later this week, we hope a positive outcome will be reached.


Loxegen's nanoparticle gene therapy for cystic fibrosis (CF) has secured a significant $1.5 million grant from the Australian Government’s $230m Medical Research Future Fund (MRFF), with additional contributions pushing the total funding to over $3million


In Australia, as across the globe, the rising cost of living continues to be a pressing concern for many, significantly affecting those living with chronic conditions such as cystic fibrosis (CF).